A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
Conditions: Potentially Resectable Hepatocellular Carcinoma Interventions: Drug: FOLFOX-HAIC+Lenvatinib+Envolizumab Sponsors: Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Study